Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsThe immune defense and therapeutic activity of antibodies in oncology have been extensively demonstrated to be one of the most useful agents for antitumor treatments, after chemotherapy, radiotherapy, and small molecule inhibitors. Most of the antibodies on immuno-oncology therapies have positive health effects as long as the antibody exists in the blood of patients. The clinical applications of antibodies directly against antigens don’t present on the tumor cells, but on cells of the immune system (i.e., immune checkpoint antibodies), indicating the beneficial outcomes of treatment, which persisted even after it’s finished. To be noticed, Creative Biolabs has tested a variety of rational combination therapy strategies, in particular, the immune checkpoint therapy with conventional cytotoxic agents to fight against severe diseases and malignant tumors.
A major breakthrough in cancer immunotherapy is the discovery of immune checkpoint proteins. These molecules present on certain immune cells that need to be activated or inactivated to effectively inhibit the immune system through many different mechanisms. Cancer cells sometimes find ways to take advantage of checkpoints to avoid being attacked by immunity. Thus, drugs that target checkpoint proteins hold a lot of promise as valuable treatments for cancers. Cytotoxic agents were originally described for their ability to interfere with nucleic acid and protein synthesis in malignant cells. More evidence that these agents might also suppress the immune system leads to their use in immune-associated diseases. The most commonly used conventional cytotoxic drugs are azathioprine, cyclophosphamide, mycophenolate mofetil, etc. Nowadays, it is of especial interest that checkpoint therapy combined with cytotoxic agents functions significantly in most clinical trials.
These are a number of efficient therapies that use a combination of agonistic antibodies or antibody-based molecules with other biological substances, such as, cytotoxic drugs. Conventional cytotoxic agents are a type of chemotherapeutic drugs unspecifically affecting cell proliferation and survival. The majority of these approaches are designed to stimulate the host immunity to act against cancer cells. As a well-recognized company in the antibody development market, Creative Biolabs has established versatile, flexible strategies to accomplish distinct therapeutic combinations for global clients. The drug agents can be provided for conjugation therapy is listed as below.
| Principles | Cytotoxic Agents |
| Inhibit topoisomerases I or topoisomerases II | Doxorubicin, Etoposide, Irinotecan, Topotecan, etc. |
| Generate DNA breaks interfering with DNA replication, RNA transcription and cell division | Busulfan, Cyclophosphamide, Carboplatin, Cisplatin, Lomustine, Melphalan, Thiotepa, etc |
In addition, anti-checkpoint antibodies in combinations exert functions satisfying these conditions.
Creative Biolabs also provides biological agents, for example, recombinant proteins, genetic materials, cytokines, bacteria, viruses, and cells (e.g. effector cells), coupled with checkpoint antibodies for many cancer treatments.
Fig.1 Immunomodulation by conventional cytotoxic drugs. (Bracci, 2013)
The cumulative findings demonstrate that anti-checkpoint antibodies are able to reprogram the organism’s immune response, redirect the antitumor immune reaction, and skew the balance on the tumor microenvironment toward the tumor’s immune destruction. As such, checkpoint molecules allow to envisage a cure for cancer. Here, Creative Biolabs offers a series of combination therapy services that simultaneously use immune checkpoint and cytotoxic drugs, showing a potentially curative option for more cancer cases and animal disease models. For more information, please feel free to contact us.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
